Transplantation immunology: Solid organ and bone marrow

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 2 SUPPL. 2, 2010, Pages

  Chinen, Javier ^a   Buckley, Rebecca H ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bone marrow transplantation; graft rejection; graft versus host disease; solid organ transplantation

Indexed keywords

ANTIMETABOLITE; AZATHIOPRINE; BASILIXIMAB; BUSULFAN; CALCINEURIN INHIBITOR; CD3 ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE ANTIBODY; CYTOKINE RECEPTOR; DACLIZUMAB; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSIDE DERIVATIVE; PREDNISONE; STEROID; T LYMPHOCYTE ANTIBODY; TACROLIMUS; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACUTE GRAFT REJECTION; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADRENOLEUKODYSTROPHY; ALLOIMMUNITY; ALOPECIA; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ANURIA; ARTICLE; BETA THALASSEMIA; BLOOD GROUP ABO SYSTEM; BONE MARROW; BONE MARROW APLASIA; BONE MARROW TRANSPLANTATION; BREAST CANCER; BRONCHIOLITIS OBLITERANS; CATARACT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC GRAFT REJECTION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; COGNITIVE DEFECT; CYSTIC FIBROSIS; CYTOPENIA; CYTOTOXIC T LYMPHOCYTE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DYSKERATOSIS; ENDOCRINE DISEASE; EOSINOPHILIA; ERYTHEMA; EXFOLIATIVE DERMATITIS; FEVER; GASTRITIS; GENE THERAPY; GENERALIZED EDEMA; GENOTYPE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GROWTH DISORDER; HEART LUNG TRANSPLANTATION; HEART TRANSPLANTATION; HELPER CELL; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATURIA; HEMOGLOBINOPATHY; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HEPATOSPLENOMEGALY; HISTOCOMPATIBILITY; HLA MATCHING; HLA TYPING; HODGKIN DISEASE; HUMAN; HURLER SYNDROME; HYPERACUTE GRAFT REJECTION; HYPERTENSION; HYPERTRICHOSIS; HYPODONTIA; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION SENSITIVITY; INTESTINE TRANSPLANTATION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEUKOCYTE; LEUKOCYTE ADHESION DEFICIENCY; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG ALVEOLUS PROTEINOSIS; LUNG CANCER; LUNG FIBROSIS; LUNG TRANSPLANTATION; LYMPHOCYTOPENIA; LYMPHOCYTOSIS; LYMPHOPROLIFERATIVE DISEASE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MORTALITY; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NECROSIS; NEPHRITIS; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; OLIGURIA; OPPORTUNISTIC INFECTION; ORGAN DONOR; ORGAN INJURY; OSTEOPOROSIS; OVARY CANCER; PLASMAPHERESIS; POLLEN; PRIORITY JOURNAL; PROTEIN LOSING GASTROENTEROPATHY; PROTEINURIA; PRURITUS; SARCOMA; SEIZURE; SEVERE COMBINED IMMUNODEFICIENCY; SICKLE CELL ANEMIA; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN EXFOLIATION; STEROID THERAPY; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THALASSEMIA; TISSUE TRANSPLANTATION; UNSPECIFIED SIDE EFFECT; VEIN OCCLUSION; WISKOTT ALDRICH SYNDROME;

ANIMALS; BONE MARROW TRANSPLANTATION; GENE THERAPY; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 76749123838     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.11.014     Document Type: Article

References (107)

1. Bach F.H., and Amos D.B. Hu-1: major histocompatibility locus in man. Science 156 (1967) 1506-1508
2. Holdsworth R., Hurley C.K., Marsh S.G., Lau M., Noreen H.J., Kempenich J.H., et al. The HLA dictionary 2008: a summary of HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and -DQ antigens. Tissue Antigens 73 (2009) 95-170
3. Klein J., and Sato A. The HLA system: first of two parts. N Engl J Med 343 (2000) 702-709
4. Marsh S.G. WHO Nomenclature Committee for Factors of the HLA System. Nomenclature for factors of the HLA system, update. Tissue Antigens 2009 74 (June 2009) 364-366
5. Klein J., and Sato A. The HLA system: second of two parts. N Engl J Med 343 (2000) 782-786
6. Kissmeyer-Nielsen F., Olsen S., Petersen V.P., and Fjeldborg O. Hyperacute rejection of kidney allografts associated with pre-existing humoral antibodies against donor cells. Lancet 2 (1966) 662-665
7. Thielke J., Kaplan B., and Benedetti E. The role of ABO-incompatible living donors in kidney transplantation: state of the art. Semin Nephrol 27 (2007) 408-413
8. Spellman S., Setterholm M., Maiers M., Noreen H., Oudshoorn M., Fernandez-Viña M., et al. Advances in the selection of HLA-compatible donors: refinements in HLA typing and matching over the first 20 years of the National Marrow Donor Program Registry. Biol Blood Marrow Transplant 14 suppl (2008) 37-44
9. Kahan B.D. Cyclosporine: a revolution in transplantation. Transplant Proc 31 suppl (1999) 14S-15S
10. Zou Y., and Stastny P. The role of major histocompatibility complex class I chain-related gene A antibodies in organ transplantation. Curr Opin Organ Transplant 14 (2009) 414-418
11. Mickelson E.M., Fefer A., Storb R., and Thomas E.D. Correlation of the relative response index with marrow graft rejection in patients with aplastic anemia. Transplantation 22 (1976) 294-330
12. Buckley R.H., Schiff S.E., Schiff R.I., Markert L., Williams L.W., Roberts J.L., et al. Hematopoietic stem cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 340 (1999) 508-516
13. Buckley R.H. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol 22 (2004) 625-655
14. Al-Lamki R.S., Bradley J.R., and Pober J.S. Endothelial cells in allograft rejection. Transplantation 86 (2008) 1340-1348
15. Karczewski J., Karczewski M., Glyda M., and Wiktorowicz K. Role of TH1/TH2 cytokines in kidney allograft rejection. Transplant Proc 40 (2008) 3390-3392
16. Knechtle S.J., and Kwun J. Unique aspects of rejection and tolerance in liver transplantation. Semin Liver Dis 29 (2009) 91-101
17. Snanoudj R., de Préneuf H., Créput C., Arzouk N., Deroure B., Beaudreuil S., et al. Costimulation blockade and its possible future use in clinical transplantation. Transpl Int 19 (2006) 693-704
18. Li X.C., Rothstein D.M., and Sayegh M.H. Costimulatory pathways in transplantation: challenges and new developments. Immunol Rev 229 (2009) 271-293
19. Atalar K., Afzali B., Lord G., and Lombardi G. Relative roles of Th1 and Th17 effector cells in allograft rejection. Curr Opin Organ Transplant 14 (2009) 23-29
20. Balin S.J., Platt J.L., and Cascalho M. Noncognate function of B cells in transplantation. Transpl Int 22 (2009) 593-598
21. Kahan B.D. Forty years of publication of transplantation proceedings-the second decade: the cyclosporine revolution. Transplant Proc 41 (2009) 1423-1437
22. Webber S.A., McCurry K., and Zeevi A. Heart and lung transplantation in children. Lancet 368 (2006) 53-69
23. Brennan D.C., Daller J.A., Lake K.D., Cibrik D., and Del Castillo D. Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 355 (2006) 1967-1977
24. Webster A.C., Woodroffe R.C., Taylor R.S., Chapman J.R., and Craig J.C. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 331 (2005) 810
25. Coenen J.J., Koenen H.J., van Rijssen E., Hilbrands L.B., and Joosten I. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4 + CD25+ regulatory T cells. Blood 107 (2006) 1018-1023
26. Matesanz R., Mahillo B., Alvarez M., and Carmona M. Global observatory and database on donation and transplantation: world overview on transplantation activities. Transplant Proc 41 (2009) 2297-2301
27. Magee C.C., and Pascual M. Update in renal transplantation. Arch Intern Med 164 (2004) 1373-1388
28. Knoll G. Trends in kidney transplantation over the past decade. Drugs 68 suppl 1 (2008) 3-10
29. Lefaucheur C., Nochy D., Andrade J., Verine J., Gautreau C., Charron D., et al. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 9 (2009) 1099-1107
30. Uchida J., Iwai T., Kato M., Machida Y., Naganuma T., Kumada N., et al. A novel approach to successful ABO-incompatible high-titer renal transplantation. Transplant Proc 40 (2008) 2285-2288
31. Kauffman H.P., Stormstad A.S., Sampson D., and Stawicki A.T. Randomized steroid therapy of human kidney transplant rejection. Transplant Proc 11 (1979) 36-38
32. Clatworthy M.R., Friend P.J., Calne R.Y., Rebello P.R., Hale G., Waldmann H., et al. Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up. Transplantation 87 (2009) 1092-1095
33. Paramesh A., Zhang R., Yau C.L., Balamuthusamy S., Shenava R., Killackey M., et al. Long-term outcome of single pediatric donor kidney transplants between African-American and non-African-American adults. Clin Nephrol 72 (2009) 55-61
34. Starzl T.E., Esquivel C., Gordon R., and Todo S. Pediatric liver transplantation. Transplant Proc 19 (1987) 3230-3235
35. Jain A., Mazariegos G., Kashyap R., Kosmach-Park B., Starzl T.E., Fung J., et al. Pediatric liver transplantation. A single center experience spanning 20 years. Transplantation 73 (2002) 941-947
36. Mowat A.P. Liver disorders in children: the indications for liver replacement in parenchymal and metabolic diseases. Transplant Proc 19 (1987) 3236-3241
37. Pillai A.A., and Levitsky J. Overview of immunosuppression in liver transplantation. World J Gastroenterol 15 (2009) 4225-4233
38. Hong J.C., Yersiz H., Farmer D.G., Duffy J.P., Ghobrial R.M., Nonthasoot B., et al. Long term outcomes for whole and segmental liver grafts in adult and pediatric liver transplant recipients: a 10- year comparative analysis of 2,988 cases. J Am Coll Surg 208 (2009) 682-689
39. Fishbein T.M. Intestinal transplantation. N Engl J Med 361 (2009) 998-1008
40. Aurora P., Edwards L.B., Christie J., Dobbels F., Kirk R., Kucheryavaya A.Y., et al. Registry of the International Society for Heart and Lung Transplantation: eleventh official pediatric lung and heart/lung transplantation report-2008. J Heart Lung Transplant 27 (2008) 978-983
41. Hertz M.I., Aurora P., Christie J.D., Dobbels F., Edwards L.B., Kirk R., et al. Registry of the International Society for Heart and Lung Transplantation: a quarter century of thoracic transplantation. J Heart Lung Transplant 27 (2008) 937-942
42. Horowitz M. The role of registries in facilitating clinical research in BMT: examples from the Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant 42 suppl 1 (2008) S1-S2
43. Martin P.J., Hansen J.A., Storb R., and Thomas E.D. Human marrow transplantation: an immunological perspective. Adv Immunol 40 (1987) 379-438
44. Appelbaum F.R. Hematopoietic-cell transplantation at 50. N Engl J Med 357 (2007) 1472-1475
45. Ljungman P., Urbano-Ispizua A., Cavazzana-Calvo M., Demirer T., Dini G., Einsele H., et al. European Group for Blood and Marrow. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 37 (2006) 439-449
46. Padmanabhan A., Reich-Slotky R., Jhang J.S., Dael S., Crowder T., Colovai A.I., et al. Use of the haematopoietic progenitor cell parameter in optimizing timing of peripheral blood stem cell harvest. Vox Sang 97 (2009) 153-159
47. Kurtzberg J. Update on umbilical cord blood transplantation. Curr Opin Pediatr 21 (2009) 22-29
48. Dwyre D.M., and Holland P.V. Transfusion-associated graft-versus-host disease. Vox Sang 95 (2008) 85-93
49. Glucksberg H., Storb R., Fefer A., Buckner C.D., Neiman P.E., Clift R.A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 18 (1974) 295-304
50. Deeg H.J., and Antin J.H. The clinical spectrum of acute graft-versus-host disease. Semin Hematol 43 (2006) 24-31
51. Carnevale-Schianca F., Leisenring W., Martin P.J., Furlong T., Schoch G., Anasetti C., et al. Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study. Biol Blood Marrow Transplant 15 (2009) 749-756
52. Finke J., Bethge W.A., Schmoor C., Ottinger H.D., Stelljes M., Zander A.R., et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 10 (2009) 855-864
53. Ogawa H., Soma T., Hosen N., Tatekawa T., Tsuboi A., Oji Y., et al. Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation. Transplantation 74 (2002) 236-243
54. Adkins D., Ratanatharathorn V., Yang H., and White B. Safety profile and clinical outcomes in a phase I, placebo-controlled study of siplizumab in acute graft-versus-host disease. Transplantation 88 (2009) 198-202
55. Pidala J., Kim J., and Anasetti C. Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 15 (2009) 881-885
56. Ferrara J.L., Levine J.E., Reddy P., and Holler E. Graft-vs-host disease. Lancet 373 (2009) 1550-1561
57. Bortin M.M., and Rimm A.A. Severe combined immunodeficiency disease. Characterization of the disease and results of transplantation. JAMA 238 (1977) 591-600
58. Sindel L.J., Buckley R.H., Schiff S.E., Ward F.E., Mickey G.H., Huang A.T., et al. Severe combined immunodeficiency with natural killer cell predominance: abrogation of graft-versus-host disease and immunologic reconstitution with HLA-identical bone marrow cells. J Allergy Clin Immunol 73 (1984) 829-836
59. Buckley R.H., Schiff S.E., Sampson H.A., Schiff R.I., Markert M.L., Knutsen A.P., et al. Development of immunity in human severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation. J Immunol 136 (1986) 2398-2407
60. Reisner Y., Itzicovitch L., Meshorer A., and Sharon N. Hematopoietic stem cell transplantation using mouse bone marrow and spleen cells fractionated by lectins. Proc Natl Acad Sci U S A 75 (1978) 2933-2936
61. Buckley R.H., and Fischer A. Bone marrow transplantation for primary immunodeficiency diseases. In: Ochs H.D., Smith C.I.E., and Puck J.M. (Eds). Primary immunodeficiency diseases: a molecular and genetic approach. 2nd ed (2006), Oxford University Press, New York 669-683
62. Sarzotti-Kelsoe M., Win C.M., Parrott R.E., Cooney M., Moser B.K., Roberts J.L., et al. Thymic output, T-cell diversity, and T-cell function in long-term human SCID chimeras. Blood 114 (2009) 1445-1453
63. Antoine C., Muller S., Cant A., Cavazzana-Calvo M., Veys P., Vossen J., et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 361 (2003) 553-560
64. Grunebaum E., Mazzolari E., Porta F., Dallera D., Atkinson A., Reid B., et al. Bone marrow transplantation for severe combined immune deficiency. JAMA 295 (2006) 508-518
65. Mazzolari E., Forino C., Guerci S., Imberti L., Lanfranchi A., Porta F., et al. Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell immunodeficiency. J Allergy Clin Immunol 120 (2007) 892-899
66. Neven B., Leroy S., Decaluwe H., Le Deist F., Picard C., Moshous D., et al. Long-term outcome after haematopoietic stem cell transplantation of a single-centre cohort of 90 patients with severe combined immunodeficiency: long-term outcome of HSCT in SCID. Blood 113 (2009) 4114-4124
67. Patel N.C., Chinen J., Rosenblatt H.M., et al. Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning. J Allergy Clin Immunol 124 (2009) 1062-1069
68. Railey M.D., Lokhnygina Y., and Buckley R.H. Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pre-transplant chemotherapy or post-transplant GVHD prophylaxis. J Pediatr 155 (2009) 834-840
69. Wengler G.S., Lanfranchi A., Frusca T., Verardi R., Neva A., Brugnoni D., et al. In-utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDX1). Lancet 348 (1996) 1484-1487
70. Flake A.W., Roncarolo M.G., Puck J.M., Almeida-Porada G., Evans M.I., Johnson M.P., et al. Treatment of X-linked severe combined immunodeficiency by in utero transplantation of paternal bone marrow. N Engl J Med 335 (1996) 1806-1810
71. Ozsahin H., Cavazzana-Calvo M., Notarangelo L.D., Schulz A., Thrasher A.J., Mazzolari E., et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood 111 (2008) 439-445
72. Filipovich A.H., Stone J.V., Tomany S.C., Ireland M., Kollman C., Pelz C.J., et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood 97 (2001) 1598-1603
73. Klein C., Lisowska-Grospierre B., LeDeist F., Fischer A., and Griscelli C. Major histocompatibility complex class II deficiency: clinical manifestations, immunologic features, and outcome. J Pediatr 123 (1993) 921-928
74. Klein C., Cavazzana-Calvo M., Le Deist F., Jabado N., Benkerrou M., Blanche S., et al. Bone marrow transplantation in major histocompatibility complex class II deficiency: a single center study of 19 patients. Blood 85 (1995) 580-587
75. Duplantier J.E., Seyama K., Day N.K., Hitchcock R., Nelson Jr. R.P., Ochs H.D., et al. Immunologic reconstitution following bone marrow transplantation for X-linked hyper IgM syndrome. Clin Immunol 98 (2001) 313-318
76. Bertrand Y., Müller S.M., Casanova J.L., Morgan G., Fischer A., and Friedrich W. Reticular dysgenesis: HLA non-identical bone marrow transplants in a series of 10 patients. Bone Marrow Transplant 29 (2002) 759-762
77. Broome C.B., Graham M.L., Saulsbury F.T., Hershfield M.S., and Buckley R.H. Correction of purine nucleoside phosphorylase deficiency by transplantation of allogeneic bone marrow from a sibling. J Pediatr 128 (1996) 373-376
78. McGhee S.A., Lloret M.G., and Stiehm E.R. Immunologic reconstitution in 22q deletion (DiGeorge) syndrome. Immunol Res 45 (2009) 37-45
79. Markert M.L. Treatment of infants with complete DiGeorge anomaly. J Allergy Clin Immunol 121 (2008) 1063
80. Markert M.L., Devlin B.H., Alexieff M.J., Li J., McCarthy E.A., Gupton S.E., et al. Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants. Blood 109 (2007) 4539-4547
81. van den Berg J.M., van Koppen E., Ahlin A., Belohradsky B.H., Bernatowska E., Corbeel L., et al. Chronic granulomatous disease: the European experience. PLoS One 4 (2009) e5234
82. Qasim W., Cavazzana-Calvo M., Davies E.G., Davis J., Duval M., Eames G., et al. Allogeneic hematopoietic stem-cell transplantation for leukocyte adhesion deficiency. Pediatrics 123 (2009) 836-840
83. Rowley S., Friedman T.M., and Korngold R. Hematopoietic stem cells transplantation for malignant diseases. In: Rich R.R. (Ed). Clinical immunology. Principles and practice (2008), Elsevier, Philadelphia 1223-1236
84. Shipley J.L., and Butera J.N. Acute myelogenous leukemia. Exp Hematol 37 (2009) 649-658
85. Koreth J., Schlenk R., Kopecky K.J., Honda S., Sierra J., Djulbegovic B.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 301 (2009) 2349-2361
86. Fernandez H.F., and Kharfan-Dabaja M.A. Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities. Cancer Control 16 (2009) 153-157
87. Sharathkumar A., Thornley I., Saunders E.F., Calderwood S., Freedman M.H., and Doyle J. Allogeneic bone marrow transplantation in children with chronic myelogenous leukemia. J Pediatr Hematol Oncol 24 (2002) 215-219
88. Barrett A.J. Understanding and harnessing the graft-versus-leukaemia effect. Br J Haematol 142 (2008) 877-888
89. Goerner M., Weber-Nordt R., Hoepfner S., Benner A., Luft T., and Ho A.D. Addition of a low fixed number of CD3+ cells to CD34-enriched allografts: effects on engraftment, graft-versus-host disease, and survival after related and unrelated peripheral stem cell transplantation. J Hematother Stem Cell Res 12 (2003) 309-320
90. Lucarelli G., Andreani M., and Angelucci E. The cure of thalassemia by bone marrow transplantation. Blood Rev 16 (2002) 81-85
91. Walters M.C., Patience M., Leisenring W., Rogers Z.R., Aquino V.M., Buchanan G.R., et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 7 (2001) 665-673
92. Gerritsen E.J., Vossen J.M., Fasth A., Friedrich W., Morgan G., Padmos A., et al. Bone marrow transplantation for autosomal recessive osteopetrosis. J Pediatr 125 (1994) 896-902
93. Mazzolari E., Forino C., Razza A., Porta F., Villa A., and Notarangelo L.D. A single-center experience in 20 patients with infantile malignant osteopetrosis. Am J Hematol 84 (2009) 473-479
94. Orchard P.J., Blazar B.R., Wagner J., Charnas L., Krivit W., and Tolar J. Hematopoietic cell therapy for metabolic disease. J Pediatr 151 (2007) 340-346
95. Gratwohl A., Passweg J., Bocelli-Tyndall C., Fassas A., van Laar J.M., Farge D., et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant 35 (2005) 869-879
96. Sandmaier B.M., Mackinnon S., and Childs R.W. Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives. Biol Blood Marrow Transplant 13 suppl 1 (2007) 87-97
97. Cavazzana-Calvo M., Hacein-Bey S., deSaint Basile G., Gross F., Yvon E., Nusbaum P., et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288 (2000) 669-672
98. Hacein-Bey-Abina S., Le Deist F., Carlier F., Bouneaud C., Hue C., De Villartay J.P., et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346 (2002) 1185-1193
99. Hacein-Bey-Abina S., Garrigue A., Wang G.P., Soulier J., Lim A., Morillon E., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy for SCID-X1. J Clin Invest 118 (2008) 3132-3142
100. Gaspar H.B., Parsley K.L., Howe S., King D., Gilmour K.C., Sinclair J., et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364 (2004) 2181-2187
101. Rabbitts T.H. LMO T-cell translocation oncogenes typify genes activated by chromosomal translocations that alter transcription and developmental processes. Genes Dev 12 (1998) 2651-2657
102. Throm R.E., Ouma A.A., Zhou S., Chandrasekaran A., Lockey T., Greene M., et al. Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood 113 (2009) 5104-5110
103. Onodera M., Nelson D.M., Sakiyama Y., Candotti F., and Blaese R.M. Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials. Acta Haematol 101 (1999) 89-96
104. Aiuti A., Cattaneo F., Galimberti S., Benninghoff U., Cassani B., Callegaro L., et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 360 (2009) 447-458
105. Santilli G., Thornhill S.I., Kinnon C., and Thrasher A.J. Gene therapy of inherited immunodeficiencies. Expert Opin Biol Ther 8 (2008) 397-407
106. Kang E.M., and Malech H.L. Advances in treatment for chronic granulomatous disease. Immunol Res 43 (2009) 77-84
107. Ott M.G., Schmidt M., Schwarzwaelder K., Stein S., Siler U., Koehl U., et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12 (2006) 401-409